NCT07050381 The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM
| NCT ID | NCT07050381 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Arteriovenous Malformation of Central Nervous System |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-06-13 |
| Primary Completion | 2025-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-06-13 with a primary completion date of 2025-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
AVMs have been reported to rupture at a formidable annual rate of 2% to 3% at natural progression, often resulting in longterm neurological deficits and poor functional outcomes.The reported risk of hemorrhagic presentation in patients with AVMs is 41% to 65%. While many studies suggest a correlation between higher hemorrhage risk and the concurrent presence of AVM and aneurysms, few authors have focused specifically on flow-related aneurysms alone. In many instances, the source of rupture is also unclear. Meta-analysis from 2016 suggested that 49.2% of hemorrhages were secondary to aneurysm rupture, 45% from AVM rupture, and 5.7% were undetermined.In a study of 302 patients, of which 52.6% had a hemorrhagic presentation, demonstrated a significant increase in rate of hemorrhage in those with flow-related aneurysms. Thus, it is necessary to figure out risk factors related to ruptured flow-related aneurysms in pAVM.
Eligibility Criteria
Inclusion Criteria: 1. pAVM with flow-related aneurysms were identified by DSA, and subarachnoid hemorrhage was confirmed by CT 2. No history of stroke, Marfan syndrome, polycystic kidney disease Exclusion Criteria: 1. pAVM without flow-related aneurysms 2. Absence of clinical data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07050381 clinical trial?
This trial is open to participants of all sexes, studying Arteriovenous Malformation of Central Nervous System. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07050381 currently recruiting?
Yes, NCT07050381 is actively recruiting participants. Contact the research team at wangyifei5323@163.com for enrollment information.
Where is the NCT07050381 trial being conducted?
This trial is being conducted at Nanjing, China, Nanjing, China.
Who is sponsoring the NCT07050381 clinical trial?
NCT07050381 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 200 participants.